vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Cannae Holdings, Inc. (CNNE). Click either name above to swap in a different company.

Cannae Holdings, Inc. is the larger business by last-quarter revenue ($103.3M vs $77.6M, roughly 1.3× Bioceres Crop Solutions Corp.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -90.0%, a 80.4% gap on every dollar of revenue. On growth, Cannae Holdings, Inc. posted the faster year-over-year revenue change (-6.0% vs -16.8%). Over the past eight quarters, Cannae Holdings, Inc.'s revenue compounded faster (-3.4% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Cannae Holdings, Inc. is a diversified holding company that primarily invests in and operates businesses across multiple sectors including financial services, restaurant and hospitality, technology, and healthcare. Its core market is the United States, and it focuses on driving long-term stakeholder value through active portfolio management and strategic operational support for its portfolio companies.

BIOX vs CNNE — Head-to-Head

Bigger by revenue
CNNE
CNNE
1.3× larger
CNNE
$103.3M
$77.6M
BIOX
Growing faster (revenue YoY)
CNNE
CNNE
+10.8% gap
CNNE
-6.0%
-16.8%
BIOX
Higher net margin
BIOX
BIOX
80.4% more per $
BIOX
-9.6%
-90.0%
CNNE
Faster 2-yr revenue CAGR
CNNE
CNNE
Annualised
CNNE
-3.4%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
CNNE
CNNE
Revenue
$77.6M
$103.3M
Net Profit
$-7.4M
$-93.0M
Gross Margin
46.8%
15.2%
Operating Margin
9.3%
-23.3%
Net Margin
-9.6%
-90.0%
Revenue YoY
-16.8%
-6.0%
Net Profit YoY
-20.2%
-101.7%
EPS (diluted)
$-0.12
$-2.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
CNNE
CNNE
Q4 25
$103.3M
Q3 25
$77.6M
$106.9M
Q2 25
$110.2M
Q1 25
$60.6M
$103.2M
Q4 24
$98.8M
$109.9M
Q3 24
$93.3M
$113.9M
Q2 24
$118.0M
Q1 24
$84.0M
$110.7M
Net Profit
BIOX
BIOX
CNNE
CNNE
Q4 25
$-93.0M
Q3 25
$-7.4M
$-68.4M
Q2 25
$-238.8M
Q1 25
$-1.6M
$-113.0M
Q4 24
$605.2K
$-46.1M
Q3 24
$-6.2M
$-13.6M
Q2 24
$-155.0M
Q1 24
$9.8M
$-89.9M
Gross Margin
BIOX
BIOX
CNNE
CNNE
Q4 25
15.2%
Q3 25
46.8%
17.1%
Q2 25
17.6%
Q1 25
39.4%
11.8%
Q4 24
42.0%
16.4%
Q3 24
40.2%
18.3%
Q2 24
21.9%
Q1 24
50.8%
14.9%
Operating Margin
BIOX
BIOX
CNNE
CNNE
Q4 25
-23.3%
Q3 25
9.3%
-12.3%
Q2 25
-55.3%
Q1 25
1.5%
-20.7%
Q4 24
14.5%
-20.0%
Q3 24
2.5%
-15.9%
Q2 24
-19.5%
Q1 24
15.7%
-36.7%
Net Margin
BIOX
BIOX
CNNE
CNNE
Q4 25
-90.0%
Q3 25
-9.6%
-64.0%
Q2 25
-216.7%
Q1 25
-2.6%
-109.5%
Q4 24
0.6%
-41.9%
Q3 24
-6.6%
-11.9%
Q2 24
-131.4%
Q1 24
11.6%
-81.2%
EPS (diluted)
BIOX
BIOX
CNNE
CNNE
Q4 25
$-2.09
Q3 25
$-0.12
$-1.25
Q2 25
$-3.93
Q1 25
$-0.02
$-1.81
Q4 24
$0.00
$-0.75
Q3 24
$-0.10
$-0.22
Q2 24
$-2.49
Q1 24
$0.14
$-1.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
CNNE
CNNE
Cash + ST InvestmentsLiquidity on hand
$15.5M
$182.0M
Total DebtLower is stronger
$70.8M
Stockholders' EquityBook value
$288.3M
$1.0B
Total Assets
$734.9M
$1.3B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
CNNE
CNNE
Q4 25
$182.0M
Q3 25
$15.5M
$233.8M
Q2 25
$66.7M
Q1 25
$38.5M
$126.2M
Q4 24
$29.2M
$131.5M
Q3 24
$32.3M
Q2 24
Q1 24
$16.4M
Total Debt
BIOX
BIOX
CNNE
CNNE
Q4 25
$70.8M
Q3 25
$68.6M
Q2 25
$168.4M
Q1 25
$170.6M
Q4 24
$181.0M
Q3 24
$181.2M
Q2 24
$78.2M
Q1 24
$79.3M
Stockholders' Equity
BIOX
BIOX
CNNE
CNNE
Q4 25
$1.0B
Q3 25
$288.3M
$1.2B
Q2 25
$1.4B
Q1 25
$345.0M
$1.7B
Q4 24
$346.3M
$1.8B
Q3 24
$346.0M
$1.9B
Q2 24
$1.9B
Q1 24
$348.5M
$2.3B
Total Assets
BIOX
BIOX
CNNE
CNNE
Q4 25
$1.3B
Q3 25
$734.9M
$1.5B
Q2 25
$1.8B
Q1 25
$798.2M
$2.1B
Q4 24
$835.2M
$2.2B
Q3 24
$827.3M
$2.3B
Q2 24
$2.2B
Q1 24
$836.1M
$2.6B
Debt / Equity
BIOX
BIOX
CNNE
CNNE
Q4 25
0.07×
Q3 25
0.06×
Q2 25
0.12×
Q1 25
0.10×
Q4 24
0.10×
Q3 24
0.10×
Q2 24
0.04×
Q1 24
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
CNNE
CNNE
Operating Cash FlowLast quarter
$14.4M
$16.0M
Free Cash FlowOCF − Capex
$12.0M
FCF MarginFCF / Revenue
11.6%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-28.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
CNNE
CNNE
Q4 25
$16.0M
Q3 25
$14.4M
$-21.6M
Q2 25
$-21.6M
Q1 25
$23.3M
$9.1M
Q4 24
$-5.4M
$-12.0M
Q3 24
$5.2M
$-31.9M
Q2 24
$-10.2M
Q1 24
$-17.4M
$-36.0M
Free Cash Flow
BIOX
BIOX
CNNE
CNNE
Q4 25
$12.0M
Q3 25
$-24.1M
Q2 25
$-23.6M
Q1 25
$7.2M
Q4 24
$-14.4M
Q3 24
$-33.6M
Q2 24
$-11.8M
Q1 24
$-37.3M
FCF Margin
BIOX
BIOX
CNNE
CNNE
Q4 25
11.6%
Q3 25
-22.5%
Q2 25
-21.4%
Q1 25
7.0%
Q4 24
-13.1%
Q3 24
-29.5%
Q2 24
-10.0%
Q1 24
-33.7%
Capex Intensity
BIOX
BIOX
CNNE
CNNE
Q4 25
3.9%
Q3 25
2.3%
Q2 25
1.8%
Q1 25
1.8%
Q4 24
2.2%
Q3 24
1.5%
Q2 24
1.4%
Q1 24
1.2%
Cash Conversion
BIOX
BIOX
CNNE
CNNE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

CNNE
CNNE

Reportable Segment Aggregation Before Other Operating Segment$94.9M92%
Other Operating Revenue$8.4M8%

Related Comparisons